Host intestinal barrier and immune pathways via microbial colonization, secreted proteins, and metabolites

The host intestinal barrier and immune pathways represent a complex, integrated system that maintains intestinal homeostasis and systemic health. This system comprises the physical mucus layer, the epithelial cell monolayer (regulated by tight junction proteins like Claudins and Occludin), and the underlying gut-associated lymphoid tissue (GALT) (PubMed: 28960120). Microbial colonization is a critical regulator of these pathways; commensal bacteria produce secreted proteins and metabolites, such as short-chain fatty acids (SCFAs) and tryptophan metabolites, which signal through host receptors like GPR43 and the Aryl hydrocarbon receptor (AHR) to strengthen barrier integrity and promote anti-inflammatory immune responses (NIH: PMC6469458). Dysregulation of these interactions—often characterized by increased intestinal permeability or "leaky gut"—is a central driver in the pathogenesis of Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), and various metabolic and autoimmune conditions (StatPearls: NBK554544). Therapeutic interventions targeting this system include probiotics, fecal microbiota transplantation, and pharmacological agents like larazotide acetate (a tight junction regulator) or biologics that neutralize pro-inflammatory cytokines like TNF-alpha. Understanding these pathways is crucial for developing precision medicines that can restore the delicate balance between the host immune system and the gut microbiome.

Other names

Gut-immune axisIntestinal mucosal barrier systemMicrobiome-host interaction pathwaysGut-microbiota-immune signaling

Modulation of epithelial tight junctions, activation of metabolite-sensing G-protein coupled receptors (e.g., GPR43), and regulation of mucosal cytokine signaling (e.g., TNF-alpha inhibition).